ICT U.S.全称是Inheritor Cell Technology (USA) INC.,重点以细胞研究与临床应用为主,在美国洛杉矶和中国北京,均拥有大型GMP标准的实验室,分别是北美再生医学研究中心
和中国实验技术中心,其中,北美再生医学研究中心以基础研究为主,而中国实验技术中心更专注于临床应用。同时,在洛杉矶地区,我们还拥有一栋占地80000平方英尺的生物样本库(临
床级),是全美为数不多的拥有双中心模式的再生医学领域跨国机构,我们致力于发展以干细胞制备、应用、治疗、制药为主的生物科技,并着眼于疾病研究、基因检测、辅助生殖、器官再
生、基因科学等人类健康服务,通过临床级生物样本库,把人类的细胞、组织、器官等生物学样本与数据完整保存下来,用于未来更多更广的医疗研究及应用发展中。
在人工智能(AI)蓬勃发展的大潮中,我们清醒地认识到,未来不能仅仅让机器变得更聪明,还应该让人类变得更健康,我们坚信——只有更健康的人类才有资格管理更聪明的机器。
细胞会改变生命……
英文简介:
ICT U.S.-Inheritor Cell Technology (USA) Inc. is a medical company specializing in the research and the clinical application of stem cells. The company owns two modern research centers: the North
American Regenerative Medicine Research Center and the China Clinical Application Center; both grand in scale and up to GMP standard. The American Center focuses on basic research, while the China
Center focuses on clinical practice. The company has also established 80,000-sq-ft biobank (clinical-grade) in the Los Angeles area. ICT prides itself as multinational and one of the few pioneers within the
regenerative medicine field with dual medical centers.
We are devoted to providing services in stem cell manufacturing, clinical application, therapy and biologics; with a commitment to services in disease research, genetic tests, assisted reproduction, organ
regeneration, genetic science, etc. The company has kept a large storage of human stem cells, tissues, organs, other biological samples within its clinical grade biobank for future medical research and
development in applications.
We are fully aware that within the ever-growing trend of artificial intelligence, the future has rendered machines to be smarter and that the future should not only render machines to be smarter, but the
enhancement of health standards as well. We therefore insist that only healthy people are eligible to manage machines with greater intelligence.
--Stem cells WILL change the lives of people